The antimalarial drug mefloquine inhibits cardiac inward rectifier K+ channels: Evidence for interference in PIP2-channel interaction

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 407-415

  López Izquierdo, Angélica ^a   Ponce Balbuena, Daniela ^a   Moreno Galindo, Eloy G ^a   Aréchiga Figueroa, Iván A ^a   Rodríguez Martínez, Martín ^a   Ferrer, Tania ^a   Rodríguez Menchaca, Aldo A ^b   Sánchez Chapula, José A ^a  

^a UNIVERSIDAD DE COLIMA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

inward rectifier potassium channel; Mefloquine; PIP2

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.3; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MEFLOQUINE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; HEART MUSCLE CELL; HYPOTHESIS; IC 50; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79955013402     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31820b7c03     Document Type: Article

References (49)

1. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45:430-475. (Pubitemid 23104127)
2. Winstanley P. Mefloquine: the benefits outweigh the risks. Br J Clin Pharmacol. 1996;42:411-413. (Pubitemid 26340140)
3. Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol. 1996;42:415-421. (Pubitemid 26340141)
4. Coker SJ, Batey AJ, Lightbown ID, et al. Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes. Br J Pharmacol. 2000;129:323-330. (Pubitemid 30072653)
5. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993;341:1054-1056. (Pubitemid 23114398)
6. + currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41-48. (Pubitemid 38068532)
7. Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:484-491. (Pubitemid 40104761)
8. Kang J, Chen XL, Wang L, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG J Pharmacol Exp Ther. 2001;299:290-296. (Pubitemid 32905146)
9. Allan D, Michell RH. Enhanced synthesis de novo ofphosphatidylinositol in lymphocytes treated with cationic amphiphilic drugs. Biochem J. 1975; 148:471-478.
10. Conrad MJ, Singer SJ. The solubility of amphipathic molecules in biological membranes and lipid bilayers and its implications for membrane structure. Biochemistry. 1981;20:808-818.
11. Andersen OS, Koeppe RE II. Bilayer thickness and membrane protein function: an energetic perspective. Annu Rev Biophys Biomol Struct. 2007;36:107-130. (Pubitemid 46998112)
12. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36:245-276. (Pubitemid 15189558)
13. Custódio JB, Almeida LM, Madeira VM. The active metabolite hydroxytamoxifen of the anticancer drug tamoxifen induces structural changes in membranes. Biochim Biophys Acta. 1993;1153:308-314. (Pubitemid 24028303)
14. Custódio JB, Almeida LM, Madeira VM. The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochim Biophys Acta. 1993;1150:123-129. (Pubitemid 23246702)
15. Zhou W, Arrabit C, Choe S, et al. Mechanism underlying bupivacaine inhibition of G protein-gated inwardly rectifying K+ channels. Proc Natl Acad Sci USA. 2001;98:6482-6487. (Pubitemid 32488263)
16. Liu B, Jia Z, Geng X, et al. Selective inhibition of Kir currents by antihistamines. Eur J Pharmacol. 2007;558:21-26. (Pubitemid 46328878)
17. + 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions. J Pharmacol Exp Ther. 2009;331:563-573.
18. + currents in part by interfering with phosphatidylinositol4,5- bisphosphate-channel interaction. J Pharmacol Sci. 2010;113:66-75.
19. Zidovetzki R, Sherman IW, Atiya A, et al. A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers. Mol Biochem Parasitol. 1989;35:199-207.
20. Zidovetzki R, Sherman IW, Maguire PA, et al. A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with lipids extracted from normal human erythrocytes. Mol Biochem Parasitol. 1990;38:33-39.
21. Gribble FM, Davis TM, Higham CE, et al. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol. 2000; 131:756-760.
22. Sakura H, Ammala C, Smith PA, et al. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett. 1995;377:338-344. (Pubitemid 26025723)
23. Inagaki N, Gonoi T, Clement JP IV, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270: 1166-1170.
24. Clement JP IV, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997;18:827-838. (Pubitemid 27232792)
25. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
26. + channels. Neuron. 1996;16:1011-1017. (Pubitemid 26171205)
27. Tucker SJ, Gribble FM, Zhao C, et al. Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature. 1997;387:179-183. (Pubitemid 27209432)
28. Pegan S, Arrabit C, Zhou W, et al. Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci. 2005;8:279-287. (Pubitemid 40300184)
29. Phillips LR, Nichols CG Ligand-induced closure of inward rectifier Kir6.2 channels traps spermine in the pore. J Gen Physiol. 2003;122:795-804. (Pubitemid 37517908)
30. 2 activation gate in inward rectifier K+ channels. Nat Neurosci. 2003;6:811-818. (Pubitemid 36929701)
31. Du X, Zhang H, Lopes C, Mirshahi T, et al. Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of Kir channels by diverse modulators. J Biol Chem. 2004;279:37271-37281. (Pubitemid 39195433)
32. Sánchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, et al. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther. 2001;297:437-445 (Pubitemid 32242605)
33. Rodríguez-Menchaca AA, Navarro-Polanco RA, Ferrer-Villada T, et al. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci USA. 2008;105:1364-1368.
34. Chevli R, Fitch CD. The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother. 1982;21:581-586. (Pubitemid 12070525)
35. Suh BC, Hille B. Regulation of ion channels by phosphatidylinositol4,5- bisphosphate. Curr Opin Neurobiol. 2005;15:370-378.
36. Enkvetchakul D, Nichols CG. Gating mechanism of KATP channels: function fits form. J Gen Physiol. 2003;122:471-480. (Pubitemid 37420843)
37. Logothetis DE, Jin T, Lupyan D, et al. Phosphoinositide-mediated gating of inwardly rectifying K(+) channels. Pflugers Arch. 2007;455:83-95. (Pubitemid 47403981)
38. 2 interactions underlie channelopathies. Neuron. 2002;34:933-944. (Pubitemid 34722283)
39. Xie LH, John SA, Ribalet B, et al. Phosphatidylinositol-4,5-bisphosphate (PIP2) regulation of strong inward rectifier Kir2.1 channels: multilevel positive cooperativity. J Physiol. 2008;586:1833-1848. (Pubitemid 351997512)
40. Assan R, Perronne C, Chotard L, et al. Mefloquine-associated hypogly-caemia in a cachectic AIDS patient. Diabete Metab. 1995;21:54-58.
41. Bateman DN, Dyson EH. Quinine toxicity. Adverse Drug React Acute PoisoningRev. 1996;4:215-233.
42. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg. 1992;95:167-179.
43. Bindschedler M, Lefèvre G, Ezzet F, et al. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol. 2000;56:375-381. (Pubitemid 30666063)
44. Touze JE, Heno P, Fourcade L, et al. The effects ofantimalarial drugs on ventricular repolarization. Am J Trop Med Hyg. 2002;67:54-60. (Pubitemid 35034320)
45. Ter Kuile FO, Nosten F, Luxemburger C Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ. 1995;73:631-642. (Pubitemid 26020629)
46. Touze JE, Heno P, Fourcade L, et al. Effects of antimalarial drugs and cardiomyocytes. Pathogenic approach and new therapeutic recommen-dations. Bull Acad Natl Med. 2006;190:439-449.
47. Lopatin AN, Nichols CG Inward rectifiers in the heart: an update on I(K1). J Mol Cell Cardiol. 2001;33:625-638. (Pubitemid 32538976)
48. Wang Z, Yue L, White M, et al. Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation. 1998;98:2422-2428. (Pubitemid 28549786)
49. Lundbaek JA. Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. J Gen Physiol. 2008;131:421-429. (Pubitemid 351620099)